Cidara Therapeutics to reduce workforce by 30%, to focus on CD388 development

Cidara Therapeutics announced a reduction in its workforce to focus on the clinical development of CD388, the company’s novel DFC candidate for influenza A and B. The planned reduction impacts approximately 30% of the Cidara workforce. These strategic initiatives are expected to substantially reduce capital needs and allow Cidara to focus on its planned Phase 2b and potential subsequent trials investigating CD388 as a single-dose, universal preventative for influenza A and B. The company continues business development discussions for its oncology DFC programs, including CBO421, a CD73 inhibitor, which recently received IND-clearance to commence a Phase 1 study.